Targeting key proteins like ITK, PI3K, SYK, and mTOR of signaling pathways which are under clinical trials in other disease conditions may open the way for the development of new therapeutic options for CTCL treatment (38). The gene discussed is MTOR; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.